Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.
Kareem Karara, PharmD, BCPS, CCHP: An interchangeable biosimilar is a biosimilar that can be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. An interchangeable biosimilar is a biologic product that’s biosimilar to the reference product. It can be expected to produce the same clinical result as the reference product in any given patient. For products that are administered more than once—chronic therapies—the risk in terms of safety or diminished efficacy in alternating or switching between the product and its reference product isn’t any greater than the risk of using the reference product without switching at all. For an interchangeable biosimilar, the FDA is going to require specific switch studies to show that it’s interchangeable.
An unbranded biologic differs from a biosimilar in the following ways: An unbranded biologic is essentially a branded biologic without the brand name on the label, but a biosimilar is different. A biosimilar is highly similar to the reference product, the branded biologic, notwithstanding any minor differences in clinically inactive components of the medication. There are no clinically meaningful differences between the biologic product and the reference product in terms of safety, purity, and potency.
Transcript edited for clarity.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More